Investigation on colistin use at the University Medical Center Hochiminh City

Antibiotic resistance has turned into a global crisis, with pathogens being less susceptible or even resistant to last-resort antibiotics. In 2010, Lim LM estimated that no new antibiotics with activity against multidrug-resistant (MDR) gram-negative bacteria such as Pseudomonas aeruginosa, Acinetobacter baumanii and Klebsiella pneumoniae are expected to be released within the next five years1. This high lights the role of colistin, an old-class antibiotic that still remains the last-line therapy in clinical settings. The spread of colistin use has recently raised concerns about resistance to this antibiotic.